Methods development for analysis of partially deglycosylated proteins and application to an HIV envelope protein vaccine candidate

被引:9
作者
Go, Eden P. [1 ]
Hewawasam, Geetha S. [1 ]
Ma, Ben J. [2 ]
Liao, Hua-Xin [2 ]
Haynes, Barton F. [2 ]
Desaire, Heather [1 ]
机构
[1] Univ Kansas, Dept Chem, Lawrence, KS 66045 USA
[2] Duke Univ, Med Ctr, Duke Human Vaccine Inst, Durham, NC USA
关键词
Glycosylation; PNGase F; Endoglycosidase; HIV; Envelope protein; Glycosylation site; HUMAN-IMMUNODEFICIENCY-VIRUS; SITE-SPECIFIC ANALYSIS; ENZYMATIC DEGLYCOSYLATION; GLYCOPEPTIDE ANALYSIS; GLYCOSYLATION SITES; GLYCOPROTEINS; IDENTIFICATION; NEUTRALIZATION; SURVIVAL; GLYCANS;
D O I
10.1016/j.ijms.2010.11.009
中图分类号
O64 [物理化学(理论化学)、化学物理学]; O56 [分子物理学、原子物理学];
学科分类号
070203 ; 070304 ; 081704 ; 1406 ;
摘要
The work presented herein describes the first comprehensive analysis of a partially deglycosylated HIV vaccine candidate envelope protein (Env). The Env, JRFL gp140 Delta CF, with 27 potential glycosylation sites, was partially deglycosylated with PNGase F as part of a strategy to generate a more immunogenic HIV vaccine, and the resulting protein glycosylation was characterized in a unique workflow using two different glycosidases, Endo H and Endo F3. This unique analysis protocol provided for coverage on 26 of the 27 glycosylation sites, and the data showed that the biochemical treatment with PNGase F resulted in a highly heterogeneous glycoprotein product that had been partially deglycosylated at most of the glycosylation sites. The protocols described in this work could be useful for characterizing the glycosylation site occupancy of other native or biochemically deglycosylated proteins. (C) 2010 Elsevier B.V. All rights reserved.
引用
收藏
页码:209 / 216
页数:8
相关论文
共 50 条
  • [1] Glycosylation Site-Specific Analysis of Clade C HIV-1 Envelope Proteins
    Go, Eden P.
    Chang, Qing
    Liao, Hua-Xin
    Sutherland, Laura L.
    Alam, S. Munir
    Haynes, Barton F.
    Desaire, Heather
    JOURNAL OF PROTEOME RESEARCH, 2009, 8 (09) : 4231 - 4242
  • [2] Optimizing the Production of gp145, an HIV-1 Envelope Glycoprotein Vaccine Candidate and Its Encapsulation in Guanosine Microparticles
    Akamine, Pearl
    Gonzalez-Feliciano, Jose A.
    Almodovar, Ruth
    Morell, Gloriner
    Rivera, Javier
    Capo-Velez, Coral M. M.
    Delgado-Velez, Manuel
    Prieto-Costas, Luis
    Madera, Bismark
    Eichinger, Daniel
    Pino, Ignacio
    Rivera, Jose H.
    Ortiz-Ubarri, Jose
    Rivera, Jose M.
    Baerga-Ortiz, Abel
    Lasalde-Dominicci, Jose A.
    VACCINES, 2023, 11 (05)
  • [3] Yeast-expressed recombinant protein of the receptor-binding domain in SARS-CoV spike protein with deglycosylated forms as a SARS vaccine candidate
    Chen, Wen-Hsiang
    Du, Lanying
    Chag, Shivali M.
    Ma, Cuiqing
    Tricoche, Nancy
    Tao, Xinrong
    Seid, Christopher A.
    Hudspeth, Elissa M.
    Lustigman, Sara
    Tseng, Chien-Te K.
    Bottazzi, Maria Elena
    Hotez, Peter J.
    Zhan, Bin
    Jiang, Shibo
    HUMAN VACCINES & IMMUNOTHERAPEUTICS, 2014, 10 (03) : 648 - 658
  • [4] Computational Design of Ancestral and Consensus Asian Dengue Envelope Protein for Vaccine Candidate
    Kemal, Rahmat Azhari
    Ivan, Jeremias
    Sandjaja, Eric Bernardus Lili
    Santosa, Audi Putra
    2019 INTERNATIONAL CONFERENCE ON BIOTECHNOLOGY AND LIFE SCIENCES (IC-BIOLIS), 2020, : 53 - 64
  • [5] Preclinical and Clinical Development of a Multi-Envelope, DNA-Virus-Protein (D-V-P) HIV-1 Vaccine
    Sealy, Robert
    Slobod, Karen S.
    Flynn, Patricia
    Branum, Kristen
    Surman, Sherri
    Jones, Bart
    Freiden, Pamela
    Lockey, Timothy
    Howlett, Nanna
    Hurwitz, Julia L.
    INTERNATIONAL REVIEWS OF IMMUNOLOGY, 2009, 28 (1-2) : 49 - 68
  • [6] Towards a vaccine for HIV infection: Role of the gp41 envelope protein
    Debre, Patrice
    Costagliola, Dominique
    Legrand, Roger
    Vieillard, Vincent
    BULLETIN DE L ACADEMIE NATIONALE DE MEDECINE, 2009, 193 (01): : 127 - 136
  • [7] Characterization of HCV Genotype 5a Envelope Proteins: Implications for Vaccine Development and Therapeutic Entry Target
    Gededzha, Maemu Petronella
    Mphahle, Maphahlanganye Jeffrey
    Selabe, Selokela Gloria
    HEPATITIS MONTHLY, 2014, 14 (11)
  • [8] cGMP production and analysis of BG505 SOSIP.664, an extensively glycosylated, trimeric HIV-1 envelope glycoprotein vaccine candidate
    Dey, Antu K.
    Cupo, Albert
    Ozorowski, Gabriel
    Sharma, Vaneet K.
    Behrens, Anna-Janina
    Go, Eden P.
    Ketas, Thomas J.
    Yasmeen, Anila
    Klasse, Per J.
    Sayeed, Eddy
    Desaire, Heather
    Crispin, Max
    Wilson, Ian A.
    Sanders, Rogier W.
    Hassell, Thomas
    Ward, Andrew B.
    Moore, John P.
    BIOTECHNOLOGY AND BIOENGINEERING, 2018, 115 (04) : 885 - 899
  • [9] A recombinant West Nile virus envelope protein vaccine candidate produced in Spodoptera frugiperda expresSF plus cells
    Bonafe, Nathalie
    Rininger, Joseph A.
    Chubet, Richard G.
    Foellmer, Harald G.
    Fader, Stacey
    Anderson, John F.
    Bushmich, Sandra L.
    Anthony, Karen
    Ledizet, Michel
    Fikrig, Erol
    Koski, Raymond A.
    Kaplan, Paul
    VACCINE, 2009, 27 (02) : 213 - 222
  • [10] A recombinant West Nile virus envelope protein vaccine candidate produced in Spodoptera frugiperda SF plus cells
    Bonafe, N.
    Rininger, J. A.
    Chubet, R. G.
    Fader, S.
    Foellmer, H. G.
    Anderson, J. F.
    Koski, Raymond
    VACCINE, 2008,